Vascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Paris Cardiovascular Research Center (PARCC), Institut National de la Santé et de la Recherche Médicale (INSERM) U970, Université Paris Cité, Paris, France.
JAMA Netw Open. 2022 Dec 1;5(12):e2245720. doi: 10.1001/jamanetworkopen.2022.45720.
High lipoprotein(a) (Lp[a]) levels are involved in the development of cardiovascular events, particularly in myocardial infarction, stroke, and peripheral artery disease. Studies assessing the Lp(a) levels associated with adverse lower-limb events are lacking.
To assess the association between Lp(a) levels and incidence of major adverse limb events in unselected hospitalized patients.
DESIGN, SETTING, AND PARTICIPANTS: This large retrospective monocentric cohort study was conducted from January 1, 2000, to December 31, 2020. Data were derived from the clinical information system of the Hôpital Européen Georges-Pompidou, a Paris-based university hospital. Patients who underwent at least 1 Lp(a) measurement at the center during the study period were included. Patients who had no follow-up data or who had the first Lp(a) measurement after the study outcome had occurred were excluded. Data analyses were performed from May 2021 to January 2022.
The primary outcome was the first inpatient major adverse limb event, defined as a major amputation, peripheral endovascular revascularization, or peripheral surgical revascularization, during follow-up. Secondary outcomes included individual components of the primary outcome. Lipoprotein(a) levels were categorized as follows: normal (<50 mg/dL), high (50 to <134 mg/dL), and very high (≥134 mg/dL); to convert Lp(a) values to milligrams per liter, multiply by 0.1.
A total of 16 513 patients (median [IQR] age, 58.2 [49.0-66.7] years; 9774 men [59.2%]) were included in the cohort. The median (IQR) Lp(a) level was 24 (10.0-60.0) mg/dL. The 1-year incidence of major adverse limb event was 2.44% in the overall population and 4.54% among patients with very high Lp(a) levels. High (adjusted accelerated failure time [AFT] exponential estimate: 0.43; 95% CI, 0.24-0.78; Benjamini-Hochberg-corrected P = .01) and very high (adjusted AFT exponential estimate: 0.17; 95% CI, 0.07-0.40; Benjamini-Hochberg-corrected P < .001) Lp(a) levels were independently associated with an increased risk of major adverse limb event.
Results of this study showed that higher Lp(a) levels were independently associated with an increased risk of a major adverse limb event in hospitalized patients. The Lp(a) measurement needs to be taken into account to improve lower-limb vascular risk assessment.
高脂蛋白(a)(Lp[a])水平与心血管事件的发展有关,特别是心肌梗死、中风和外周动脉疾病。缺乏评估与不良下肢事件相关的 Lp(a)水平的研究。
评估未选择的住院患者中 Lp(a)水平与主要不良肢体事件发生率之间的关系。
设计、地点和参与者:这是一项大型回顾性单中心队列研究,于 2000 年 1 月 1 日至 2020 年 12 月 31 日进行。数据来自巴黎乔治蓬皮杜欧洲医院的临床信息系统。在研究期间至少在中心进行了一次 Lp(a)测量的患者被纳入。无随访数据或首次 Lp(a)测量发生在研究结果之后的患者被排除在外。数据分析于 2021 年 5 月至 2022 年 1 月进行。
主要结局是随访期间首次住院的主要不良肢体事件,定义为主要截肢、外周血管内血运重建或外周手术血运重建。次要结局包括主要结局的各个组成部分。Lp(a)水平分类如下:正常(<50mg/dL)、高(50 至 <134mg/dL)和非常高(≥134mg/dL);要将 Lp(a)值转换为毫克/分升,请乘以 0.1。
共纳入 16513 例患者(中位数[IQR]年龄为 58.2[49.0-66.7]岁;9774 例男性[59.2%])。Lp(a)水平的中位数(IQR)为 24(10.0-60.0)mg/dL。总体人群的 1 年主要不良肢体事件发生率为 2.44%,非常高 Lp(a)水平患者的发生率为 4.54%。高(调整加速失效时间[AFT]指数估计值:0.43;95%CI,0.24-0.78;经 Benjamini-Hochberg 校正的 P=.01)和非常高(调整 AFT 指数估计值:0.17;95%CI,0.07-0.40;经 Benjamini-Hochberg 校正的 P<.001)Lp(a)水平与主要不良肢体事件风险增加独立相关。
本研究结果表明,较高的 Lp(a)水平与住院患者主要不良肢体事件风险增加独立相关。需要考虑 Lp(a)测量以改善下肢血管风险评估。